Methods for treating and diagnosing blinding eye diseases
This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
1. A method for treating reticular pseudodrusen (RPD) disease, comprising ophthalmically administering to a subject in need thereof an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
each of R 1 and R 2 is independently H or a C 1 -C 6 alkyl and
R 3 is H or a C 1 -C 6 alkyl.
2. The method of claim 1 , wherein the compound of Formula I is bindarit.
3. The method of claim 1 , wherein the method comprises reducing the amount of pseudodrusen in the subject.
4. The method of claim 3 , wherein the method comprises reducing the amount of pseudodrusen in any one of the foveal area, perifoveal area, and juxtafoveal area of the subject's eye.
5. The method of claim 3 , wherein the reduction in the amount of pseudodrusen in the subject is assessed using optical coherence tomography (OCT).
6. The method of claim 1 , wherein the method comprises reducing expansion of pseudodrusen in the subject.
7. The method of claim 6 , wherein the method comprises reducing expansion of pseudodrusen in any one of the foveal area, perifoveal area, and juxtafoveal area of the subject's eye.
8. The method of claim 1 , wherein the method further comprises administering an additional therapeutic agent.
9. The method of claim 8 , wherein the additional therapeutic agent is one or more of an anti-vascular endothelial growth factor (VEGF) agent, an angiotensin-converting enzyme (ACE) inhibitor, a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, a renin inhibitor, a steroid, and an agent that modulates autophagy.
10. The method of claim 1 , wherein the bindarit is formulated for ophthalmic administration.
11. The method of claim 10 , wherein the ophthalmic administration is intravitreal or intraocular administration.
12. The method of 10 , wherein the bindarit is formulated for sustained release.
13. The method of 1 , wherein the bindarit is ophthalmically administered using sustained release.